LymphedemaV1, Pmc, Corpus, bibRecord, 002F61

Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ

Identifieur interne : 002F61 ( Pmc/Corpus ); précédent : 002F60; suivant : 002F62

Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ

Auteurs : Hilary M. Shapiro-Wright ; Thomas B. Julian

Source :

Journal of the National Cancer Institute. Monographs [ 1052-6773 ] ; 2010.

RBID : PMC:5161062

Abstract

Ductal carcinoma in situ (DCIS) of the breast historically has been a disease detected by physical examination, diagnosed by open surgical biopsy, and treated by mastectomy and axillary dissection. It is now increasingly detected by screening mammography, diagnosed by needle core biopsy, and treated by lumpectomy, with axillary dissection having been abandoned and sentinel node biopsy being used in axillary staging.

However, outcomes related to sentinel node biopsy in DCIS have not been validated in well-controlled clinical trials. Current guideline recommendations are to use sentinel node biopsy when needle core biopsy is highly suspicious for invasive cancer or where there is a high-risk DCIS when lumpectomy identifies invasive breast cancer with the DCIS, or when mastectomy is performed for extensive DCIS. Routine use of sentinel node biopsy for DCIS is not supported.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161062

DOI: 10.1093/jncimonographs/lgq026
PubMed: 20956820
PubMed Central: 5161062

Links to Exploration step

PMC:5161062

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ</title>
<author><name sortKey="Shapiro Wright, Hilary M" sort="Shapiro Wright, Hilary M" uniqKey="Shapiro Wright H" first="Hilary M." last="Shapiro-Wright">Hilary M. Shapiro-Wright</name>
</author>
<author><name sortKey="Julian, Thomas B" sort="Julian, Thomas B" uniqKey="Julian T" first="Thomas B." last="Julian">Thomas B. Julian</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">20956820</idno>
<idno type="pmc">5161062</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161062</idno>
<idno type="RBID">PMC:5161062</idno>
<idno type="doi">10.1093/jncimonographs/lgq026</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">002F61</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">002F61</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ</title>
<author><name sortKey="Shapiro Wright, Hilary M" sort="Shapiro Wright, Hilary M" uniqKey="Shapiro Wright H" first="Hilary M." last="Shapiro-Wright">Hilary M. Shapiro-Wright</name>
</author>
<author><name sortKey="Julian, Thomas B" sort="Julian, Thomas B" uniqKey="Julian T" first="Thomas B." last="Julian">Thomas B. Julian</name>
</author>
</analytic>
<series><title level="j">Journal of the National Cancer Institute. Monographs</title>
<idno type="ISSN">1052-6773</idno>
<idno type="eISSN">1745-6614</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p>Ductal carcinoma in situ (DCIS) of the breast historically has been a disease detected by physical examination, diagnosed by open surgical biopsy, and treated by mastectomy and axillary dissection. It is now increasingly detected by screening mammography, diagnosed by needle core biopsy, and treated by lumpectomy, with axillary dissection having been abandoned and sentinel node biopsy being used in axillary staging.</p>
<p>However, outcomes related to sentinel node biopsy in DCIS have not been validated in well-controlled clinical trials. Current guideline recommendations are to use sentinel node biopsy when needle core biopsy is highly suspicious for invasive cancer or where there is a high-risk DCIS when lumpectomy identifies invasive breast cancer with the DCIS, or when mastectomy is performed for extensive DCIS. Routine use of sentinel node biopsy for DCIS is not supported.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
  <front><journal-meta><journal-id journal-id-type="nlm-ta">J Natl Cancer Inst Monogr</journal-id>
<journal-id journal-id-type="hwp">jncimono</journal-id>
<journal-id journal-id-type="publisher-id">jncmon</journal-id>
<journal-title-group><journal-title>Journal of the National Cancer Institute. Monographs</journal-title>
</journal-title-group>
<issn pub-type="ppub">1052-6773</issn>
<issn pub-type="epub">1745-6614</issn>
<publisher><publisher-name>Oxford University Press</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">20956820</article-id>
<article-id pub-id-type="pmc">5161062</article-id>
<article-id pub-id-type="doi">10.1093/jncimonographs/lgq026</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Articles</subject>
</subj-group>
</article-categories>
<title-group><article-title>Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Shapiro-Wright</surname>
<given-names>Hilary M.</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Julian</surname>
<given-names>Thomas B.</given-names>
</name>
</contrib>
</contrib-group>
<aff><bold>Affiliations of authors:</bold>
 Department of Human Oncology, Allegheny General Hospital, Pittsburgh, PA (HMS-W, TBJ); Medical Affairs, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA (TBJ); Human Oncology, Drexel University College of Medicine, Pittsburgh, PA (TBJ); Allegheny Breast Care Center, Pittsburgh, PA (TBJ)</aff>
<author-notes><corresp><bold>Correspondence to:</bold>
 Thomas B. Julian, MD, Department of Human Oncology, Allegheny General Hospital, 320 East North Avenue, Pittsburgh, PA 15212 (e-mail: <email>tjulian@wpahs.org</email>
).</corresp>
</author-notes>
<pub-date pub-type="ppub"><month>10</month>
<year>2010</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>1</day>
<month>10</month>
<year>2011</year>
</pub-date>
<pmc-comment> PMC Release delay is 12 months and 
 						0 days and was based on the . </pmc-comment>
      <volume>2010</volume>
<issue>41</issue>
<fpage>145</fpage>
<lpage>149</lpage>
<permissions><copyright-statement>© The Author 2010. Published by Oxford University Press.</copyright-statement>
<copyright-year>2010</copyright-year>
</permissions>
<abstract><p>Ductal carcinoma in situ (DCIS) of the breast historically has been a disease detected by physical examination, diagnosed by open surgical biopsy, and treated by mastectomy and axillary dissection. It is now increasingly detected by screening mammography, diagnosed by needle core biopsy, and treated by lumpectomy, with axillary dissection having been abandoned and sentinel node biopsy being used in axillary staging.</p>
<p>However, outcomes related to sentinel node biopsy in DCIS have not been validated in well-controlled clinical trials. Current guideline recommendations are to use sentinel node biopsy when needle core biopsy is highly suspicious for invasive cancer or where there is a high-risk DCIS when lumpectomy identifies invasive breast cancer with the DCIS, or when mastectomy is performed for extensive DCIS. Routine use of sentinel node biopsy for DCIS is not supported.</p>
</abstract>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F61 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 002F61 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Pmc
   |étape=   Corpus
   |type=    RBID
   |clé=     PMC:5161062
   |texte=   Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i   -Sk "pubmed:20956820" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ

Sentinel Lymph Node Biopsy and Management of the Axilla in Ductal Carcinoma In Situ

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki